ReviewLeukemia2024

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

Hagop Kantarjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.